Upgrade to SI Premium - Free Trial

Form 3 Lakewood-Amedex Biothera For: Apr 17 Filed by: DeRoma Leonard James

May 1, 2026 6:32 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
DeRoma Leonard James

(Last) (First) (Middle)
8031 COOPER CREEK BLVD UNIT 103

(Street)
UNIVERSITY PARK FL 34201

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/17/2026
3. Issuer Name and Ticker or Trading Symbol
Lakewood-Amedex Biotherapeutics Inc. [ LABT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock; $0.0001 par value 187,736
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants 04/01/2016 02/29/2028 Common Stock 40,541 5.92 D
Warrants 04/01/2017 02/29/2028 Common Stock 13,514 5.92 D
Warrants 01/12/2018 07/11/2028 Common Stock 33,784 5.92 D
Warrants 07/12/2020 07/11/2030 Common Stock 8,446 2.37 D
Warrants 07/12/2021 07/11/2031 Common Stock 8,446 2.78 D
Warrants 07/12/2022 07/11/2032 Common Stock 8,446 2.13 D
Explanation of Responses:
/s/ Leonard DeRoma 05/01/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings